{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:00:20Z","timestamp":1789203620708,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.2353\/jmoldx.2009.080150","type":"journal-article","created":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T19:53:31Z","timestamp":1251316411000},"page":"482-487","source":"Crossref","is-referenced-by-count":30,"title":["Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Elia","family":"Mattarucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lo Curto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Campiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2353\/jmoldx.2009.080150_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.2353\/jmoldx.2009.080150_bib2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2009.080150_bib3","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","article-title":"Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse","volume":"115","author":"Mughal","year":"2001","journal-title":"Br J Haematol"},{"key":"10.2353\/jmoldx.2009.080150_bib5","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.leukres.2004.06.012","article-title":"CML cytogenetic relapse after cessation of imatinib therapy","volume":"29","author":"Usuki","year":"2005","journal-title":"Leuk Res"},{"key":"10.2353\/jmoldx.2009.080150_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2009.080150_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ncponc0110","article-title":"Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?","volume":"2","author":"Goldman","year":"2005","journal-title":"Nat Clin Practice Oncol"},{"key":"10.2353\/jmoldx.2009.080150_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","article-title":"Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era","volume":"12","author":"Goldman","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"10.2353\/jmoldx.2009.080150_bib10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib11","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib13","first-page":"235","article-title":"The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"10.2353\/jmoldx.2009.080150_bib14","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib15","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2009.080150_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for \u201charmonizing\u201d current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib18","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2009.080150_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000077557","article-title":"A standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia","volume":"112","author":"M\u00fcller","year":"2004","journal-title":"Acta Haematol"},{"key":"10.2353\/jmoldx.2009.080150_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"10","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2009.080150_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.2353\/jmoldx.2009.080150_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leukemia Lymphoma"},{"key":"10.2353\/jmoldx.2009.080150_bib24","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","article-title":"Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia","volume":"5","author":"Barnes","year":"2006","journal-title":"Cell Cycle"},{"key":"10.2353\/jmoldx.2009.080150_bib25","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V87.6.2588.bloodjournal8762588","article-title":"Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation","volume":"87","author":"Zhang","year":"1996","journal-title":"Blood"},{"key":"10.2353\/jmoldx.2009.080150_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/gcc.20568","article-title":"Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia","volume":"47","author":"Mattarucchi","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.2353\/jmoldx.2009.080150_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2353\/jmoldx.2006.050111","article-title":"Establishment and study of different real-time polymerase chain reaction assays for the quantification of cells with deletions of chromosome 7","volume":"8","author":"Mattarucchi","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.2353\/jmoldx.2009.080150_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MPH.0b013e31803b958e","article-title":"Monitoring the isochromosome i(7)(q10) in the bone marrow of patients with Shwachman syndrome by real-time quantitative PCR","volume":"29","author":"Porta","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.2353\/jmoldx.2009.080150_bib29","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2404708","article-title":"Monosomy 7 in myeloid malignancies: parental origin and monitoring by real-time quantitative PCR","volume":"21","author":"Porta","year":"2007","journal-title":"Leukemia"},{"key":"10.2353\/jmoldx.2009.080150_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.2353\/jmoldx.2009.080150_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515781060267X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152515781060267X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T19:24:40Z","timestamp":1590089080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152515781060267X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S152515781060267X"],"URL":"https:\/\/doi.org\/10.2353\/jmoldx.2009.080150","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}